Enhancing Cancer Immunotherapy with Nanomedicine

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2020 Feb 2

PMID 32005979

Citations 235

Authors

Darrell J Irvine

Eric L Dane

Affiliations

Soon will be listed here.

Abstract

Therapeutic targeting of the immune system in cancer is now a clinical reality and marked successes have been achieved, most notably through the use of checkpoint blockade antibodies and chimeric antigen receptor T cell therapy. However, efforts to develop new immunotherapy agents or combination treatments to increase the proportion of patients who benefit have met with challenges of limited efficacy and/or significant toxicity. Nanomedicines - therapeutics composed of or formulated in carrier materials typically smaller than 100 nm - were originally developed to increase the uptake of chemotherapy agents by tumours and to reduce their off-target toxicity. Here, we discuss how nanomedicine-based treatment strategies are well suited to immunotherapy on the basis of nanomaterials' ability to direct immunomodulators to tumours and lymphoid organs, to alter the way biologics engage with target immune cells and to accumulate in myeloid cells in tumours and systemic compartments. We also discuss early efforts towards clinical translation of nanomedicine-based immunotherapy.

Citing Articles

Iterative selection of lipid nanoparticle vaccine adjuvants for rapid elicitation of tumoricidal CD8⁺ T cells.

Luo Y, Zhou S, Song Y, Huang W, Wilding G, Jablonski J Bioact Mater. 2025; 48:189-199.

PMID: 40046011 PMC: 11880734. DOI: 10.1016/j.bioactmat.2025.01.028.

Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines.

Maksymova L, Pilger Y, Nuhn L, Van Ginderachter J Mol Cancer. 2025; 24(1):65.

PMID: 40033293 PMC: 11877942. DOI: 10.1186/s12943-025-02270-5.

Recent advances in nanomedicine for the diagnosis and therapy of thyroid disorders.

Sahare P, Ruiz-Manriquez L, Anguiano B, Banerjee A, Pathak S, Duttaroy A 3 Biotech. 2025; 15(3):67.

PMID: 40012722 PMC: 11850684. DOI: 10.1007/s13205-025-04234-4.

Evaluating the In Situ Effects of Whole Protein Coronas on the Biosensing of Antibody-Immobilized Nanoparticles Using Two-Color Fluorescence Nanoparticle Tracking Analysis.

Joung H, Jang G, Jeong J, Lim G, Han S Nanomaterials (Basel). 2025; 15(3).

PMID: 39940196 PMC: 11820540. DOI: 10.3390/nano15030220.

Injectable hyaluronic acid-based hydrogel niches to create localized and time-controlled therapy delivery.

Torresan V, Gandin A, Contessotto P, Zanconato F, Brusatin G Mater Today Bio. 2025; 31:101510.

PMID: 39935896 PMC: 11810838. DOI: 10.1016/j.mtbio.2025.101510.

References

Pluen A, Boucher Y, Ramanujan S, McKee T, Gohongi T, Di Tomaso E . Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A. 2001; 98(8):4628-33. PMC: 31885. DOI: 10.1073/pnas.081626898. View

Biot C, Rentsch C, Gsponer J, Birkhauser F, Jusforgues-Saklani H, Lemaitre F . Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012; 4(137):137ra72. DOI: 10.1126/scitranslmed.3003586. View

Duan X, Chan C, Guo N, Han W, Weichselbaum R, Lin W . Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. J Am Chem Soc. 2016; 138(51):16686-16695. PMC: 5667903. DOI: 10.1021/jacs.6b09538. View

Netea M, Joosten L, Latz E, Mills K, Natoli G, Stunnenberg H . Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352(6284):aaf1098. PMC: 5087274. DOI: 10.1126/science.aaf1098. View

Song W, Shen L, Wang Y, Liu Q, Goodwin T, Li J . Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun. 2018; 9(1):2237. PMC: 5993831. DOI: 10.1038/s41467-018-04605-x. View

Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H . In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2018; 14(1):89-97. DOI: 10.1038/s41565-018-0319-4. View

Zheng Y, Tang L, Mabardi L, Kumari S, Irvine D . Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors. ACS Nano. 2017; 11(3):3089-3100. PMC: 5647839. DOI: 10.1021/acsnano.7b00078. View

Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T . Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann Oncol. 2018; 29(11):2163-2174. PMC: 6290929. DOI: 10.1093/annonc/mdy423. View

Charych D, Hoch U, Langowski J, Lee S, Addepalli M, Kirk P . NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models. Clin Cancer Res. 2016; 22(3):680-90. DOI: 10.1158/1078-0432.CCR-15-1631. View

10.

Miller M, Chandra R, Cuccarese M, Pfirschke C, Engblom C, Stapleton S . Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci Transl Med. 2017; 9(392). PMC: 6681815. DOI: 10.1126/scitranslmed.aal0225. View

11.

Hoang B, Ernsting M, Roy A, Murakami M, Undzys E, Li S . Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism. Biomaterials. 2015; 59:66-76. PMC: 4442760. DOI: 10.1016/j.biomaterials.2015.04.032. View

12.

Lebre F, Hearnden C, Lavelle E . Modulation of Immune Responses by Particulate Materials. Adv Mater. 2016; 28(27):5525-41. DOI: 10.1002/adma.201505395. View

13.

Hammerich L, Marron T, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S . Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019; 25(5):814-824. DOI: 10.1038/s41591-019-0410-x. View

14.

Nakamura T, Miyabe H, Hyodo M, Sato Y, Hayakawa Y, Harashima H . Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J Control Release. 2015; 216:149-57. DOI: 10.1016/j.jconrel.2015.08.026. View

15.

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

16.

Lebbe C, Weber J, Maio M, Neyns B, Harmankaya K, Hamid O . Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol. 2014; 25(11):2277-2284. PMC: 4990834. DOI: 10.1093/annonc/mdu441. View

17.

Munn D, Mellor A . The tumor-draining lymph node as an immune-privileged site. Immunol Rev. 2006; 213:146-58. DOI: 10.1111/j.1600-065X.2006.00444.x. View

18.

Jahchan N, Mujal A, Pollack J, Binnewies M, Sriram V, Reyno L . Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Front Immunol. 2019; 10:1611. PMC: 6673698. DOI: 10.3389/fimmu.2019.01611. View

19.

Quintin J, Saeed S, Martens J, Giamarellos-Bourboulis E, Ifrim D, Logie C . Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe. 2012; 12(2):223-32. PMC: 3864037. DOI: 10.1016/j.chom.2012.06.006. View

20.

Marill J, Mohamed Anesary N, Paris S . DNA damage enhancement by radiotherapy-activated hafnium oxide nanoparticles improves cGAS-STING pathway activation in human colorectal cancer cells. Radiother Oncol. 2019; 141:262-266. DOI: 10.1016/j.radonc.2019.07.029. View